11C-YJH08 for Prostate Cancer
This study is evaluating if PET imaging using 11C-YJH08 can be useful for detecting certain cell receptor expression in tumor cells in patients with prostate cancer that has spread to other parts of the body (metastatic).
See full descriptionAbout the trial for Prostate Cancer
Treatment Groups
This trial involves 2 different treatments. 11C-YJH08 is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
About The Treatment
Eligibility
This trial is for male patients aged 18 and older. There are 10 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether 11C-YJH08 will improve 3 primary outcomes and 5 secondary outcomes in patients with Prostate Cancer. Measurement will happen over the course of Up to day 1 follow-up.
Patient Q & A Section
Does prostate cancer run in families?
Findings from a recent study suggest that sporadic PCa has a familial component. PCa could be involved in many genes. We hypothesize a genetic model for BRCA1 mutation carriers, which might explain the age at onset and the familial occurrence of PCa and warrant further investigation.
Is 11c-yjh08 safe for people?
Although 11C-YJH08 was well tolerated and associated with no significant adverse events, this study did not show superiority over placebo on primary outcomes, and thus merits further investigation.
Have there been any new discoveries for treating prostate cancer?
Despite the large number of published research articles on treatment of prostate cancer, many questions remain unanswered. There are no data on the cost effectiveness of these treatments, nor have they been proven effective in all aspects of the disease. A better understanding of the biology of prostate cancer can lead to improved treatment options.
What is the average age someone gets prostate cancer?
To our knowledge, this is the largest database study to report average age of onset of PCa. The findings suggest that the mean age at time of diagnosis of PCa increased steadily from 1990 to 2006; however, the age distribution remained skewed toward younger ages, with 7.4% of all diagnoses occurring at age <40 years.
What is the latest research for prostate cancer?
There are many topics in the biomedical sciences that have benefited from the development and application of advanced technologies and concepts. Novel approaches that aim at identifying early and aggressive forms of prostate cancer will hopefully lead to better outcomes for patients with this disease. Scientists have also been able to identify possible biomarkers that may guide the diagnosis and treatment of prostate cancer. Prospective trials evaluating innovative diagnostic tools and therapies are now being conducted on a regular basis.
What are common treatments for prostate cancer?
The use of AAS for [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) prevention should be discouraged because it does not improve survival but increases the rate of non-organ-confined cancers. Radical therapy is preferable to watchful waiting ± salvage radiation therapy after failure of radical therapy.
How does 11c-yjh08 work?
Findings from a recent study suggest that yjh08 exerts its antitumoral properties via inhibition of angiogenesis, potentiation of apoptosis and modulation of cell cycle progression. Findings from a recent study highlights the therapeutic potential of 11C-yjh08 in urological malignancies.
What does 11c-yjh08 usually treat?
The treatment outcome of patients with T1N0M0 prostate cancer was similar to that observed for patients with locally advanced prostate cancer treated with standard therapy including external beam radiotherapy and/or brachytherapy. Recent findings suggest that 11c-yjh08 can be proposed as a therapeutic option for patients with localized prostate cancer.
How quickly does prostate cancer spread?
Recent findings suggest that prostate cancer may be more likely to spread if it first arises in the peripheral zone rather than the transitional zone. Further studies are needed to determine whether this finding can be exploited to improve treatment strategies.
What are the common side effects of 11c-yjh08?
11C-yjh08 is well tolerated with clinically relevant adverse events. For example, headache occurred in 25% of patients who received 11C-yjh08; however, this does not appear to have resulted in any serious consequences in those patients. Further studies are required to clarify the full range of adverse events associated with 11C-yjh08.
How many people get prostate cancer a year in the United States?
• About 1 in 6 men will develop prostate cancer during their lifetime. • About 1 in 10 men will die of prostate cancer. • Rates differ considerably among racial groups. • Men are more likely to develop prostate cancer at younger ages, in higher socioeconomic groups, and in cities.